168317-99-5

Usage

Structure

Pyrrolidine derivative with an iodine-substituted benzoyl group attached to the nitrogen atom

Potential applications

Medicinal chemistry and drug development

Biological activities

Exhibits various biological activities as a pyrrolidine derivative

Iodine atom

Confers specific properties and reactivity to the compound

Organic synthesis

Useful in organic synthesis due to the presence of the iodine atom

Building block

Can be used as a building block for more complex molecules

Research

Further research may reveal a wider range of applications in chemical and pharmaceutical industries

Upstream product

• 123-75-1 pyrrolidine 
• 1711-02-0 4-iodobenzoic acid chloride 
• 619-58-9 4-iodobenzoic acid 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 619-44-3 methyl 4-iodobenzoate 

Downstream Products

• 1092459-28-3 3-(difluoromethyl)-1-[4-(1-pyrrolidinylcarbonyl)phenyl]-4,5,6,7-tetrahydro-1H-indazole 
• 1092459-48-7 1'-[4-(1-pyrrolidinylcarbonyl)phenyl]-3'-(trifluoromethyl)-1',4',6',7'-tetrahydrospiro[1,3-dioxolane-2,5'-indazole] 
• 630385-38-5 1-[1-(4-iodophenyl)-1-(methyl)ethyl]pyrrolidine 
• 1022930-35-3 1-[4-(1-pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole 
• 1022930-30-8 1-[4-(1-pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole 
• 858676-60-5 1-(4-iodobenzyl)pyrrolidine 
• 1092459-30-7 1-[4-(1-pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-1,4,6,7-tetrahydro-5H-indazol-5-one 

Relevant academic research and scientific papers

A practical catalytic reductive amination of carboxylic acids

We report reductive alkylation reactions of amines using carboxylic acids as nominal electrophiles. The two-step reaction exploits the dual reactivity of phenylsilane and involves a silane-mediated amidation followed by a Zn(OAc)2-catalyzed amide reduction. The reaction is applicable to a wide range of amines and carboxylic acids and has been demonstrated on a large scale (305 mmol of amine). The rate differential between the reduction of tertiary and secondary amide intermediates is exemplified in a convergent synthesis of the antiretroviral medicine maraviroc. Mechanistic studies demonstrate that a residual 0.5 equivalents of carboxylic acid from the amidation step is responsible for the generation of silane reductants with augmented reactivity, which allow secondary amides, previously unreactive in zinc/phenylsilane systems, to be reduced.

Borinic Acid Catalysed Reduction of Tertiary Amides with Hydrosilanes: A Mild and Chemoselective Synthesis of Amines

A reduction of various aryl, alkyl, and α,β-unsaturated amides with phenylsilane, catalysed by a borinic acid, is reported. The unprecedented reaction was carried out under very mild conditions and led to useful amines. Furthermore, the reaction tolerates a variety of functional groups. Initial investigations implicated that an intermediate diarylhydroborane is involved in the reaction mechanism.

On DABAL-Me3 promoted formation of amides

The range and utility of DABAL-Me3 couplings of methyl esters and free carboxylic acids with primary and secondary amines under a variety of conditions (reflux, sealed tube, microwave) has been compared for a significant range of coupling partners of relevance to the preparation of amides of interest in pharmaceutical chemistry. Commercial microwave reactors promote the fastest couplings and allow the use of significantly sterically hindered amines (primary and secondary) and carboxylic acids derivatives. The influence of microwave energy on the reaction system was shown to be typically related to thermal effects (over-pressuring and superheating).

COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

Compounds of formula (I), and salts and solvates thereof are provided: Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods fo

COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE

Compound of formula (I) and salts thereof are provided: wherein X, Y, Z, R1, R2 and R3 are as defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

A novel safety-catch linker for the solid-phase synthesis of amides and esters

(matrix presented) A new safety-catch linker for solid-phase organic synthesis is described. Synthesis and attachment of the linker to the solid phase was achieved via a simple and high-yielding strategy. The linker was exemplified by acylation to form unactivated amides, activation of the linker, and cleavage to release acyl moieties. Acids, amides, or esters were released under mild conditions and with exceptionally high purity. The reactivities of unactivated and activated amides are compared.